Shire Adds Equetro To CNS Product Lineup
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended-release carbamazepine clears FDA for treatment of bipolar disorder. In clinical trials, Equetro did not produce "significant weight gain or blood sugar changes," Shire says. Launch is expected in the first quarter of 2005.